Want to join the conversation?
$PFE 2Q15 PR: IBRANCE continues to be well received by oncologists treating postmenopausal women with ER /HER2- advanced breast cancer. Approx. 3,000 healthcare practitioners are already prescribing IBRANCE, which is up from 800 at the end of 1Q15. Current first-line market share in this patient population was approx. 22%, up from 10% during 1Q15.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.